If you're planning to attend the 2024 Alzheimer's Association International Conference (AAIC) in a couple of weeks, be sure to catch our poster, "Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case-control study using Dutch primary care data" on Sunday, July 28, 2024, 08:00–16:15. Learn more at https://aaic.alz.org/ #alzheimers #AAIC2024 #dementia #primarycaredata
Over ons
PHARMO Institute for Drug Outcomes Research uses patient-centric data to derive real-life insights into value of medicines for the individual patients. We provide tailor-made research solutions to questions on Disease Epidemiology, Drug Utilization Research, Utilization of Healthcare Resources, Health Outcomes Research, Risk management, Patient tracking for patient related outcomes and validation, Drug safety and Health Economic Support. Our specialist areas are Cardiovascular and Metabolic disease, Oncology and Autoimmune Disease, Respiratory Disease, and Mother& Child health. We can tailor-make studies for the needs of our clients in all indications. PHARMO has established experience and manages a large network of key stakeholders in the therapeutic areas mentioned here. We also provide medical writing, scientific publications and literature review services.
- Website
-
http://www.pharmo.nl
Externe link voor PHARMO Institute for Drug Outcomes Research
- Branche
- Geneesmiddelenproductie
- Bedrijfsgrootte
- 11 - 50 medewerkers
- Hoofdkantoor
- Utrecht
- Type
- Particuliere onderneming
- Specialismen
- pharmacoepidemiology, drug safety en health outcomes
Locaties
-
Primair
van Deventerlaan 30-40
Utrecht, 3528 AE, NL
Medewerkers van PHARMO Institute for Drug Outcomes Research
-
Michiel Meulendijk
Senior Researcher & Data Expert in Medical Informatics
-
Jetty Overbeek
Head of PHARMO Research at PHARMO Institute for Drug Outcomes Research
-
Hilda de Jong
Senior Researcher at the PHARMO Institute for Drug Outcomes Research
-
Ilona Verburg
Data scientist PHARMO
Updates
-
New research from our own Eline Houben highlights the importance of coordination between general practitioners (GPs) and obstetricians/gynecologists in the provision of routine medical care during pregnancy. Of 140,976 pregnancies in the Netherlands between 2004 and 2020, registration in The Teratology Information Service, the knowledge centre of Lareb on safety of drugs used before and during pregnancy and during breastfeeding, was only available for 13%. The limited registration introduces a risk of prescribing teratogenic medications and increases the likelihood of pregnant women experiencing an adverse event. Registration rates appear to improve in later years. Increased collaboration between GPs and midwives is strongly encouraged. Read the full research brief in English at https://lnkd.in/eq7SVzgj or in Dutch at https://lnkd.in/eh-9pwig #realworldevidence #realworlddata #carecoordination #drugsafety #adversevent #adverseventmonitoring #pharmacovigilance #teratogenic #riskmanagement #publichealth
-
We are proud to be presenting at the upcoming Royal Statistical Society (RSS) International Conference 2024. Be sure to add our rapid-fire talk to your diary, Enhancing the identification and profiling of patients with heart failure in a population-based cohort through linkage of primary and secondary care data, on September 4, 15:10-15:50pm. For more information about the conference, visit https://lnkd.in/e6mUTj5C #RSS2024 #heartfailure #statistics #caredata #patientprofiling
Conference 2024
rss.org.uk
-
We are looking forward to the upcoming 2024 Alzheimer's Association International Conference (AAIC). If you'll be in Philadelphia for the conference, be sure to catch our poster, "Cognitive symptoms and medical history prior to mild cognitive impairment and dementia diagnosis: a retrospective case-control study using Dutch primary care data" on Sunday, July 28, 2024, 8:00 AM – 4:15 PM EDT For more information about the conference, visit https://aaic.alz.org/ #alzheimers #AAIC2024 #dementia #primarycaredata
AAIC | July 28-Aug. 1, 2024 | Alzheimer's Association
aaic.alz.org
-
If you're at the DIA Global Annual Meeting in San Diego, connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD, via the DIA meeting app. Don't miss tomorrow's forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: - Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity - Naomi Boxall, PhD, General Manager, PHARMO Institute - Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA - Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University - Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company For more information, visit https://buff.ly/3WSqtDH #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety
DIA 2024 Global Annual Meeting: #218: Long-Term Safety of Approved Medic...
dia2024globalannualmeeting.sched.com
-
The DRUG INFORMATION ASSOCIATION (DIA) Global Annual Meeting is around the corner! If you'll be there, connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD. Be sure to catch our forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: - Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity - Naomi Boxall, PhD, General Manager, PHARMO Institute - Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA - Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University - Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company During the forum we will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/44V8RJs Reach out to our colleagues in the DIA meeting app or email contact@lumanity.com to schedule time to meet with us on-site. #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety
DIA 2024 Global Annual Meeting: #218: Long-Term Safety of Approved Medic...
dia2024globalannualmeeting.sched.com
-
The DIA Global Annual Meeting is just a couple of weeks away! If you're planning to be there, be sure to connect with our colleagues on-site, including Steve Weisman and Naomi Boxall through the DIA meeting app or by emailing contact@lumanity.com to schedule time to meet on-site. Don't miss the forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity, Naomi Boxall, PhD, General Manager, PHARMO Institute, Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA, Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University, and Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company The forum will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/3KoloeT #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety
DIA 2024 Global Annual Meeting: #218: Long-Term Safety of Approved Medic...
dia2024globalannualmeeting.sched.com
-
We are excited to be at the table at the upcoming hybrid workshop, Joint HMA/EMA Big Data Steering Group workshop on RWE methods, taking place June 14 at the EMA premises in Amsterdam as well as online. Hilda de Jong will be joining other stakeholders to share views of the RWE reflection paper, priorities for further regulatory guidance development and collaboration beyond the reflection paper, and novel RWE methods in regulatory decision-making. The workshop is targeted towards regulatory bodies, academia, the pharmaceutical industry, health technology assessment (HTA), patients and healthcare professionals. For more information, and to register for virtual attendance, visit https://lnkd.in/gejCu6D7 #EMA #EuropeanMedicinesAgency #HMA #RWE #regulatory #HTA #realworldevidence #decisionmaking
Joint HMA/EMA Big Data Steering Group workshop on RWE methods
ema.europa.eu
-
We are looking forward to the upcoming DRUG INFORMATION ASSOCIATION (DIA) Global Annual Meeting next month! If you're attending, be sure to connect with our colleagues on-site, including Naomi Boxall and Steven Weisman PhD. Don't miss our forum, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events featuring: – Steven M. Weisman, PhD, Global President, Clinical and Regulatory, Lumanity – Naomi Boxall, PhD, General Manager, PHARMO Institute – Gerald Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, CDER, FDA – Vera Ehrenstein, DrSc, MPH, Professor, Department of Clinical Medicine, Dept of Clinical Epidemiology, Aarhus University – Claudia A Salinas, PhD, Senior Director, GPS Pharmacoepidemiology, Eli Lilly and Company During the forum we will explore the critical need for longitudinal data in drug safety research, examining the strengths and limitations of different data collection approaches and examine collaborative opportunities with regulators and organizations, such as SIGMA, to address these research needs and enhance patient care. For more information on this session, visit https://buff.ly/4bt4LdV Reach out to our colleagues in the DIA meeting app or e-mail contact@lumanity.com to schedule time to meet with us on-site. #DIA2024 #DIAGlobal #DIAAnnual #SafetyStudies #ClinicalDevelopment #DrugDevelopment #Regulatory #Epidemiology #DrugSafety
DIA 2024 Global Annual Meeting: #218: Long-Term Safety of Approved Medic...
dia2024globalannualmeeting.sched.com
-
Check out our new article with our partners at Lumanity https://buff.ly/3UU2QYJ and be sure to catch our forum at the upcoming DIA Global Annual Meeting, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events, during which we will explore the critical need for longitudinal data in drug safety research as well as the strengths and limitations of different data collection approaches. #realworlddata #RWD #patientsafety #drugsafety #outcomesresearch #epidemiology #healthcareoutcomes #DIA2024
Understanding the long-term effects of medications is essential for ensuring patient safety and optimizing healthcare outcomes. However, comprehensive longitudinal data to study late effects of drugs over extended periods can be hard to come by. Read more in our new article at https://buff.ly/4avSXq0 and be sure to catch our forum at the upcoming DIA Global Annual Meeting, Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events, during which we will explore the critical need for longitudinal data in drug safety research as well as the strengths and limitations of different data collection approaches. #realworlddata #RWD #patientsafety #drugsafety #outcomesresearch #epidemiology #healthcareoutcomes #DIA2024
Longitudinal Data in Pharmacoepidemiology and Outcomes Research
https://lumanity.com